The contribution of residual malignant cells contaminating the autologous graft with the occurrence of post-transplant relapse in acute myeloid leukemia (AML) is still unclear. The presence of a specific molecular marker (the PML/RAR␣ rearrangement) in acute promyelocytic leukemia (APL) offers the opportunity to investigate better the pathogenesis of disease recurrence after transplant. We report an APL patient who received highdose chemotherapy and peripheral blood stem cell (PBSC) autograft in second hematologic remission. Two leukaphereses that tested PML/RAR␣ positive by RT-PCR were obtained during the post-reinduction hematopoietic recovery, while the patient also tested PCR positive in the BM, and was reinfused after myeloablative chemotherapy (BUCY4), when the patient had spontaneously converted to PCR negative in the marrow. At present, he remains in continuous molecular and hematologic remission 22 months after PBSC transplantation. This is the second report of an APL patient who was transplanted in molecular remission with a PML/RAR␣-positive PBSC autograft. As in the previous report, the prolonged clinical and molecular remission experienced post-transplant suggests that autologous PBSC infusion is still worthy of consideration for patients with APL in spite of the detection of PML/RAR␣-positive cells in the PBSC collections. Possible underlying mechanisms and the potential role of molecular monitoring of the graft, as well as the host, before and after transplant, in patients with APL undergoing autologous HSCT are also discussed.
Introduction
In addition to the typical clinical and morphologic features, acute promyelocytic leukemia (APL) shows a characteristic CD34 − /DR − immunophenotype, a striking sensitivity to anthracyclines, a specific reciprocal translocation t (15;17) and, as a result of this genetic abnormality, the PML/RAR␣ gene rearrangement. This hybrid gene confers on leukemic cells from APL patients a special sensitivity to the differentiationinducing agent all-trans retinoic acid (ATRA), which induces hematological complete remission in virtually 100% of PML/RAR␣-positive cases. 1 A further distinctive characteristic, not observed in other subtypes of AML, is the prognostic value of monitoring studies of residual disease during remission using reverse transcriptase-polymerase chain reaction (RT-PCR) of the PML/RAR␣ hybrid. [2] [3] [4] [5] [6] [7] In light of these clinical and biologic characteristics, several aspects of the therapeutic strategy in APL are currently under revision. Most recent treatment protocols for newly diagnosed patients include variable combinations of ATRA and conven- 13 and rarely for patients in first remission.
In the setting of autologous HSCT, the potential reinfusion of leukemic blasts together with normal hematopoietic stem cells has always been of major concern. Although, in principle, a leukemia-free inoculum should provide higher probabilities of cure, the real contribution of blast contamination in the graft, to the occurrence of relapse is still debated, at least in AML. The presence of a specific molecular marker in APL confers an excellent opportunity to study this pathogenic mechanism of relapse in this particular subtype of AML.
We herein report an APL patient who remains in second molecular and hematological remission 22 months after a PML/RAR␣-positive peripheral blood stem cell (PBSC) autograft performed while the BM was PML/RAR␣-negative. The potential role of molecular monitoring of the graft, as well as the host, before and after transplant, and their clinical relevance in patients with APL undergoing autologous HSCT is also carefully addressed in the light of recent preliminary evidence.
Case report
A 32-year-old man was admitted to the hospital in October 1993 because of fever. Laboratory tests showed a WBC count of 2.5 × 10 9 /l, a hemoglobin level of 8.8 g/dl, and a platelet count of 9 × 10 9 /l. The bone marrow aspirate disclosed a picture of heavy infiltration by atypical promyelocytes with abundant Auer rods, consistent with a diagnosis of typical hypergranular APL. The leukemic population was CD13 and CD33 positive, and lacked CD34 and HLA-DR expression. Unfortunately, chromosomal and RT-PCR analysis were not available at presentation. Treatment with ATRA (Hoffman-La Roche, Basel, Switzerland), at a dose of 45 mg/m 2 daily orally, was immediately started. Four days later, chemotherapy treatment consisting of daunorubicin (60 mg/m 2 /day × 3 days) and cytarabine (200 mg/m 2 /day × 7 days) was added because of increasing WBC count. One month later, he achieved hematologic CR. According to the APL-93 protocol of the European APL Group, 12 the patient went on to receive a consolidation chemotherapy course, similar to the remission induction one, and an intensification treatment including daunorubicin (45 mg/m 2 /day × days 1-3) and cytarabine (1 g/m 2 /12 h, days 1-4). In April 1994, maintenance therapy was started with 6-mercaptopurine (90 mg/m 2 daily orally) and methotrexate (15 mg/m 2 weekly i.m.). In October 1994, a routine marrow examination confirmed hematological CR, but the presence of a bcr3 type PML/RAR␣ fusion gene was detected by RT-PCR. Two additional RT-PCR tests performed at 4 monthly intervals, while the patient was still in hematologic CR, confirmed the presence of the PML/RAR␣ fusion gene in BM cells (Figure 1 ). In November 1995, the patient had overt hematological relapse. A second CR was achieved after administering ATRA followed 2 weeks later, due to leukocytosis, by a combination of mitoxantrone (12 mg/m 2 /day × days 1-3), cytarabine (500 mg/m 2 /day × days 1-3 and 8-10) and etoposide (200 mg/m 2 /day × days 8-10). Two stem cell aphereses were collected during the post-induction hematopoietic recovery. Filgrastim (5 g/kg/day) had been previously administered for shortening neutropenia and mobilizing hematopoietic progenitor cells. The CD34
+ cell yield was 20.9 × 10 6 /kg. Despite hematological CR, both leukaphereses, and the bone marrow obtained at this time (day 30 post-chemotherapy), tested RT-PCR positive for the PML/RAR␣ hybrid. No further chemotherapy was administered as consolidation. Forty-two days later, unexpectedly, a bone marrow aspirate performed immediately prior to a PBSC autograft tested RT-PCR negative for the PML/RAR␣. The BUCY4 protocol was used as conditioning regimen. The post-transplant period was uneventful, and the patient achieved 1 × 10 9 PMN/l and 20 × 10 9 platelets/l on days +21 and +42, respectively. Eighteen months after the autograft, the patient remains alive and well in hematological and molecular remission. RT-PCR analyses of the PML/RAR␣ hybrid performed on bone marrow samples obtained 2, 5, 7, 12, 16 and 22 months after transplant were always negative (Figure 1 ).
Materials and methods
Mononuclear cells were obtained from bone marrow by Ficoll-Hypaque density gradient centrifugation and the cells distributed in aliquots containing more than 5 million and stored at −80°C in 1 ml of guanidium iso-thiocyanate solution. Total RNA was extracted following the procedure described by Chomczynski and Sacchi.
14 One microgram of total RNA was reverse-transcribed using M-MLV reverse transcriptase and random examers as primers. For the detection of the PML/RAR␣ rearrangement we followed the procedure of Lo Coco et al, 2 that briefly consists in a semi-nested PCR using the set of primers M4-R5/R8, that differentiates bcr3 (single 324 bp amplification band) from bcr1-bcr2 (multiband pattern), or M2-R5/R8, that distinguishes the types bcr1 and bcr2 based on their different size. The AML1 gene, which is ubiquitously expressed by blood mononuclear cells, was co-amplified in each experiment in order to check the RNA quality as well as the efficiency of the reverse transcription step. The amplified PCR products were detected by electrophoresis through a 1.2% agarose minigel stained with ethidium bromide.
Discussion
In addition to the clinical, morphological and cytogenetic characteristics, another distinctive feature of APL is the presence of the PML/RAR␣ fusion gene in virtually all patients, a RT-PCR amplifiable molecular marker. Sequential studies of the PML/RAR␣ transcript by RT-PCR in different series [2] [3] [4] [5] [6] [7] have demonstrated as allowing an accurate monitoring of minimal residual disease during remission and to enable the prediction of hematological relapse.
Preliminary data from a recent Italian report 13 also suggest that RT-PCR analysis of the PML/RAR␣ rearrangement from bone marrow samples obtained immediately before conditioning therapy is a reliable indicator of clinical outcome after autologous bone marrow transplantation (ABMT). In this report, involving 15 patients with APL undergoing ABMT in second CR (14 conditioned with the BAVC regimen), seven patients were PCR positive and eight PCR negative for PML/RAR␣ in their pretransplant bone marrow. All seven PCR-positive patients remained PCR positive during follow-up and relapsed 2-9 months from ABMT, whereas all the PCRnegative patients remained PCR negative and only one of them had a hematologic relapse at 10 months. These results led to the suggestion of the use of alternative aggressive approaches, such as unrelated allogeneic HSCT in patients with PCR positivity, after reinduction and consolidation chemotherapy. Another small sample size preliminary study 15 has shown that long-term remission after HSCT in APL is associated with elimination, at least below RT-PCR sensitivity levels of 10 −4 , of cells carrying the PML/RAR␣ fusion gene, and that continued PCR positivity predicts subsequent relapse. In this series, three out of five patients who had PML/RAR␣ transcripts in bone marrow prior to transplantation (allogeneic BMT in two and autologous PBSCT in one) became PCR negative early after transplant and remained in CR, which suggests that in some patients the preparative regimen effectively suppresses the malignant clone below the limit of detection by RT-PCR, and clearly contributes in curing APL. 15 The importance of the prognostic value of minimal residual disease in APL patients undergoing HSCT is underlined by the fact that a recent survey of the Working Party on Acute Leukemia of the European Co-operative Group for Bone Marrow Transplantation on 362 APL transplanted patients failed to disclose significant prognostic factors of outcome. 16 In AML subtypes other than APL, direct evidence that the reinfusion of neoplastic cells may contribute to leukemia relapse after autologous HSCT has been brought forward by gene-marking studies. 17 However, the relative importance of this mechanism, in comparison with the persistence of leukemia in the patient after conditioning therapy, that is, how many relapses are directly and solely caused by leukemic contamination of the graft, still remains undetermined. As far as we know, gene-marking studies have not yet been performed in APL and thus, both indirect and direct evidence that the later mechanism could play a role in relapse after HSCT in APL patients is still lacking.
We believe that RT-PCR analysis of the PML/RAR␣ fusion gene might provide a privileged tool to investigate the mechanism of leukemia relapse in APL patients undergoing autologous HSCT. Unfortunately, the patients included in two previous reports dealing with the prognostic value of RT-PCR analysis of the PML/RAR␣ transcript after autologous HSCT, 13, 15 had been autografted in a matched molecular condition between the host and the graft (ie patients with PML/RAR␣-positive bone marrow were autografted with a positive bone marrow harvest, and patients with PML/RAR␣-negative marrow were autografted with a negative marrow harvest). 13, 15 On the other hand, in some cases of autologous PBSCT included in one of these studies, 15 information about the molecular status of the PBSC graft was not available. Thus, the direct contribution of the persistence of leukemic cells in the graft to disease recurrence cannot be ascertained from these reports.
In this paper we report the outcome of a patient with APL in second hematologic CR and in molecular remission in the bone marrow just prior to conditioning, and who received a PBSC autograft bearing cells with the PML/RAR␣ fusion transcript. Remarkably, the patient remains in molecular remission after a 22 months follow-up. As occurred in this case, the only other previously reported patient 16 autografted with a PML/RAR␣-positive PBSC inoculum while in molecular CR, remained in prolonged molecular remission after transplantation. 18 In that case report, one of three aphereses used for HSCT was PML/RAR␣ positive. In contrast to the case reported here, the aphereses were collected while the bone marrow tested PCR negative. 18 Although we can speculate that a greater number of PML/RAR␣-positive cells was infused in our patient, neither did this fact result in leukemic relapse. These reports clearly suggest that leukemic contamination of PBSC grafts in APL patients undergoing autologous PBSCT while bone marrow is in molecular remission before transplant do not necessarily lead to leukemic relapse, and do not preclude long-term remission, and possibly cure.
The absence of disease recurrence in both patients, ie the one reported by Ruiz-Argü elles et al 18 and our case, could be explained by still unclear mechanisms of surveillance and control of low numbers of leukemic cells or by the nonclonogenic nature of the PML/RAR␣-positive cells present in the graft. The persistence of differentiating elements which carry the specific rearrangement and are spontaneously cleared during follow-up is a common event in patients receiving ATRA. In addition, long-term hematopoiesis after autologous PBSCT would be sustained by the subset of CD34
− progenitor cells administered, and these immature progenitors have been shown to lack the PML/RAR␣ rearrangement in APL patients. 19 In conclusion, this report of a new APL patient who remains in long-term molecular remission after receiving a PML/RAR␣-positive PBSC transplant induces revision of the role that the reinfusion of PCR-positive cells has in relapse in this particular subtype of AML. The available data suggest that the autologous PBSC transplant is still worth considering for patients with APL in spite of detecting the presence of PML/RAR␣-positive cells in PBSC collections.
